Clinical Trial Update: Ph 1 Trial of ADI PEG 20 Plus Sorafenib to Treat Patients With Liver Cancer [Phase 1]

View source ↗

Summary

A Phase 1 study evaluating ADI-PEG 20 in combination with sorafenib for hepatocellular carcinoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• ADI-PEG 20 (pegylated arginine deiminase)
• Nexavar (Sorafenib)

Snippet

Sponsor: Polaris Group | Conditions: Hepatocellular Carcinoma | Phase 1 | Status: COMPLETED